Literature DB >> 19959340

The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review.

Cleo L Crunelle1, Michelle L Miller, Jan Booij, Wim van den Brink.   

Abstract

Drug dependence is a chronic brain disease characterized by recurrent episodes of relapse, even when the person is motivated to quit. Relapse is a major problem and new pharmacotherapies are needed to prevent relapse episodes. The nicotinic acetylcholine receptor (nAChR) plays an important role in nicotine dependence, alcohol consumption and cue-induced cocaine craving. Stimulation of the nAChR has been found to alter and modulate cell firing in brain areas important for the maintenance of drug dependence. Varenicline, an alpha4beta2 nAChR partial agonist and an alpha7 nAChR full agonist registered for the treatment of nicotine dependence, significantly reduces nicotine craving and prevents relapse. In addition, varenicline reduces alcohol consumption in rats. Based on a review of the available literature, we hypothesize a potential role for varenicline in the prevention of relapse in patients recovering from drug dependence other than nicotine dependence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19959340     DOI: 10.1016/j.euroneuro.2009.11.001

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  15 in total

1.  Probing the Allosteric Role of the α5 Subunit of α3β4α5 Nicotinic Acetylcholine Receptors by Functionally Selective Modulators and Ligands.

Authors:  Caroline Ray; Erik J Soderblom; Yushi Bai; F Ivy Carroll; Marc G Caron; Larry S Barak
Journal:  ACS Chem Biol       Date:  2017-01-24       Impact factor: 5.100

2.  Stopping smoking during first year of substance use treatment predicted 9-year alcohol and drug treatment outcomes.

Authors:  Janice Y Tsoh; Felicia W Chi; Jennifer R Mertens; Constance M Weisner
Journal:  Drug Alcohol Depend       Date:  2010-11-02       Impact factor: 4.492

3.  Chronic exposure to nicotine is associated with reduced reward-related activity in the striatum but not the midbrain.

Authors:  Emma Jane Rose; Thomas J Ross; Betty Jo Salmeron; Mary Lee; Diaa M Shakleya; Marilyn Huestis; Elliot A Stein
Journal:  Biol Psychiatry       Date:  2011-10-26       Impact factor: 13.382

4.  Role of nicotinic acetylcholine receptors in the effects of cocaine-paired contextual stimuli on impulsive decision making in rats.

Authors:  Xiaohu Xie; Amy A Arguello; Andrew M Reittinger; Audrey M Wells; Rita A Fuchs
Journal:  Psychopharmacology (Berl)       Date:  2012-04-20       Impact factor: 4.530

5.  The Role of the Habenula in Nicotine Addiction.

Authors:  Philip R Baldwin; Raul Alanis; Ramiro Salas
Journal:  J Addict Res Ther       Date:  2011-10-20

6.  Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor.

Authors:  Mark S Moehle; Tristano Pancani; Nellie Byun; Samantha E Yohn; George H Wilson; Johnathan W Dickerson; Daniel H Remke; Zixiu Xiang; Colleen M Niswender; Jürgen Wess; Carrie K Jones; Craig W Lindsley; Jerri M Rook; P Jeffrey Conn
Journal:  Neuron       Date:  2017-12-20       Impact factor: 17.173

7.  Contributions of β2 subunit-containing nAChRs to chronic nicotine-induced alterations in cognitive flexibility in mice.

Authors:  Robert D Cole; Rachel L Poole; Dawn M Guzman; Thomas J Gould; Vinay Parikh
Journal:  Psychopharmacology (Berl)       Date:  2014-10-04       Impact factor: 4.530

Review 8.  Recent Advances in Nicotinic Receptor Signaling in Alcohol Abuse and Alcoholism.

Authors:  Shafiqur Rahman; Eric A Engleman; Richard L Bell
Journal:  Prog Mol Biol Transl Sci       Date:  2015-11-03       Impact factor: 3.622

9.  Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders.

Authors:  Sarah C Akerman; Mary F Brunette; Douglas L Noordsy; Alan I Green
Journal:  Curr Addict Rep       Date:  2014-09-27

Review 10.  [The roles of habenula and related neural circuits in neuropsychiatric diseases].

Authors:  Yuxing Wu; Shihong Zhang; Zhong Chen
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.